Chemeq silent on ASIC query
Thursday, 09 September, 2004
Perth veterinary drug developer Chemeq Limited (ASX:CMQ) has announced it will issue a replacement prospectus after the Australian Securities and Investments Commission placed an interim stop order on the prospectus it issued late last month for a rights issue to raise $9.94 million.
Chemeq’s founder and chief executive, Dr Graham Melrose, declined to elaborate on the problem with the original prospectus, saying it was "a matter between Chemeq and ASIC".
The announcement said ASIC had reviewed Chemeq’s prospectus and had “expressed views in relation to certain statements” in it.
The company said Chemeq did not necessarily agree with the positions adopted by ASIC, but would work with ASIC to resolve the issue as quickly as possible, so that a replacement prospectus could be lodged, the interim stop order lifted, and the proposed timetable for the rights issue not substantially affected.
The financially troubled company ended a two-week trading suspension on the ASX last week by announcing it had successful placed 4.1 million shares at $2.40 per share, and would make a underwritten, renounceable rights issue offering shareholders one new share for every 11 shares they already hold, exercisable on June 30 next year.
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
